The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC)

Current Drug Targets

Volumn 11, Issue 1, 2010, Pages 67-73

  Wagner, Timothy D ^a   Yang, Gary Y ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Concurrent chemoradiation; Locally advanced non small cell lung cancer; Pemetrexed; Radiation therapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; NAVELBINE; PACLITAXEL; PEMETREXED; VINBLASTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; ESOPHAGITIS; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; RADIOSENSITIVITY; RADIOSENSITIZATION; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; LUNG TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 77949437912     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790030956     Document Type: Review

References (52)

1. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 2006; 8: 195-202.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22: 330-53.
3. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: A metaanalysis. Cancer 1995; 76: 593-601.
4. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-23.
5. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-15.
6. Curran WJ, Scott CB, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22: 621 (abstr 2499).
7. Albain KS, Crowley JJ, Turrisi AT III, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. J Clin Oncol 2002; 20: 3454-60.
8. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23: 5883-91.
9. Vokes EE, Herndon JE II, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25: 1698-704.
10. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21: 2004-10.
11. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26: 5755-60.
12. Curran WJ. Treatment of locally advanced non-small cell lung cancer: what we have and have not learned over the past decade. Semin Oncol 2005; 32: (2 Suppl 3) S2-5.
13. Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005; 23; 5910-17.
14. Arriagada R, Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY, et al. ASTRO plenary: effect of chemotherapy on locally advanced non small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 1991; 20: 1183-90.
15. Bogart JA, Govindan R. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 285-7.
16. Emami B, Mirkovic N, Scott C, Byhardt R, Graham MV, James Andras E, et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer 2003; 41: 207-14.
17. Leibel SA, Fuks Z, Zelefsky MJ, Wolden SL, Rosenzweig KE, Alektiar KM, et al. Intensity modulated radiotherapy. Cancer J 2002; 8: 164-76.
18. Intensity Modulated Radiation Therapy Collaborative Working Group: Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880-914.
19. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep 2005; 7: 255-9.
20. Murshed H, Liu HH, Liao Z, Barker JL, Wang X, Tucker SL, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1258-67.
21. Haasbeek CJ, Spoelstra FO, Lagerwaard FJ, van Sörnsen de Koste JR, Cuijpers JP, Slotman BJ, et al. Impact of audio-coaching on the position of lung tumors. Int J Radiat Oncol Biol Phys 2008; 71: 1118-23.
22. Keall P, Vedam S, George R, Bartee C, Siebers J, Lerma F, et al. The clinical implementation of respiratory-gated intensity-modulated radiotherapy. Med Dosim 2006; 31: 152-62.
23. Kong FM, Ten HRK, Schipper MJ, Sullivan MA, Chen M, Lopez C, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63: 324-33.
24. Yang GY, Wagner TD, Jobe BA, Thomas CR. The role of positron emission tomography in esophageal cancer. Gastrointest Cancer Res 2008; 2: 3-9.
25. Abratt RP, Willcox PA, Smith JA. Lung cancer in patients with borderline lung functions-Zonal lung perfusion scans at presentation and lung function after high dose irradiation. Radiother Oncol 1990; 19: 317-22.
26. Lavrenkov K, Christian JA, Partridge M, Niotsikou E, Cook G, Parker M, et al. A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. Radiother Oncol 2007; 83: 156-62.
27. Yaremko BP, Guerrero TM, Noyola-Martinez J, Guerra R, Lege DG, Nguyen LT, et al. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys 2007; 68: 562-71.
28. Heidelberger C, Griesbach L, Montag BJ, Mooren D, Cruz O, Schnitzer RJ, et al. Studies on fluorinated pyrimidines. II. Effects of transplanted tumors. Cancer Res 1958; 18: 305-17.
29. Sischy B. The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 1985; 11: 1587-93.
30. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002; 52(5): 1381-8.
31. Shih C, ChenVJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-23.
32. Grindey GB, Shih C, Barnett CJ. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (Abstr). Proc Am Soc Clin Oncol 1992; 33: 411.
33. Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990; 19: 1411-17.
34. Buchholz DJ, Lepek KJ, Rich TA, Murray D. 5-fluorouracil- radiationminteractions in human colon adenocarcinoma cells. Int J Radiat Oncol Biol Phys 1995; 32: 1053-58.
35. Blackstock AW, Kwock I, Branch C, Zeman EM, Tepper JE. Tumor retention of 5-floururacil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1996: 36: 641-48.
36. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003; 3: 145-56.
37. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatinversus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
38. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2002; 13: 737-41.
39. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, et al. Phase II study of pemetrexed-gemcitabine combination in patientswith advanced-stage non-small cell lung cancer. Clin Cancer Res 2004; 10: 5439-46.
40. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11: 690-6.
41. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
42. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
43. Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009; 35: 364-73.
44. http://www.cancer.gov/cancertopics/druginfo/fda-pemetrexeddisodium Accessed on July 4, 2009.
45. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: 18s (suppl; abstr CRA8000).
46. Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007; 13: 515-22.
47. Govindan R, Bogart J, Wang X, Hodgson L, Kratzke R, Vokes EE. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009; 27: 15s, (suppl; abstr 7505).
48. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
49. Vokes EE, Senan S, Treat JA, Iscoe NA. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009; 10: 193-8.
50. Brade AM, Bezjak A, MacRae R, Laurie SA, Pond GR, Wang L, et al. A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26: (May 20 suppl; abstr 7550).
51. Heinzerling JH, Hughes RS, Govindan R, Bradley JD, Schiller J, Peng G, et al. A phase I study of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced non-small cell lung cancer (LANSCLC). J Clin Oncol 2009; 27: 15s (suppl; abstr 7545).
52. Gadgeel SM, Ruckdeschel JC, Wozniak A, Patel B, Heilbrun LK, Chen W, et al. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2008; 26: (May 20 suppl; abstr 7569).